Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on VF, Raises Price Target to $42

Baird Maintains Outperform on VF, Raises Price Target to $42

Baird analyst Jonathan Komp maintains VF (NYSE:VFC) with a Outperform and raises the price target from $40 to $42.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Baird analyst Jonathan Komp maintains VF (NYSE:VFC) with a Outperform and raises the price target from $40 to $42.

Bit Brother Reached Potential Collaboration With Blockworx1 For Sell Price Of $1.2M

By Benzinga Newsdesk

January 25, 10:49 AM

Bit Brother Limited (the "Company," "we", "BTB" or "Bit Brother") (NASDAQ:BTB), through its subsidiary Bit Brother New York Inc ("BTB NY"), signed an LOI with Blockworx1

BTB

Amryt Receives Orphan Drug Designation From The FDA For Mycapssa For The Treatment Of Carcinoid Syndrome

By Benzinga Newsdesk

July 14, 7:03 AM

Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that the US Food and Drug

AMYT